Abstract
Combination chemotherapy has become the primary strategy for treating cancer; however, the clinical success of combination treatments is limited by the distinct pharmacokinetics (PK) of different drugs, which lead to nonuniform distribution and an inability to coordinate dosing regimes at the site of the tumor. In the first half of this review, we will discuss the recent development of nanoparticlebased combination strategies to overcome these limitations. Nanoparticles are able to co-encapsulate and carry multiple drugs with different hydrophobicities while maintaining precise ratiometric loading and delivery. They can also temporally sequence the release of multiple drugs and reduce undesirable PK interactions. In the second half of this review, we will touch on the key factors that affect nanoparticle stability and distribution. Nanoparticles provide a promising strategy to improve combinatorial cancer treatments by better controlling PK and metabolic differences between drugs.
Keywords: Combination therapy, drug interaction, nanoparticles, pharmacokinetics.
Current Drug Metabolism
Title:Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Volume: 15 Issue: 8
Author(s): Yarong Liu, Jennifer Rohrs and Pin Wang
Affiliation:
Keywords: Combination therapy, drug interaction, nanoparticles, pharmacokinetics.
Abstract: Combination chemotherapy has become the primary strategy for treating cancer; however, the clinical success of combination treatments is limited by the distinct pharmacokinetics (PK) of different drugs, which lead to nonuniform distribution and an inability to coordinate dosing regimes at the site of the tumor. In the first half of this review, we will discuss the recent development of nanoparticlebased combination strategies to overcome these limitations. Nanoparticles are able to co-encapsulate and carry multiple drugs with different hydrophobicities while maintaining precise ratiometric loading and delivery. They can also temporally sequence the release of multiple drugs and reduce undesirable PK interactions. In the second half of this review, we will touch on the key factors that affect nanoparticle stability and distribution. Nanoparticles provide a promising strategy to improve combinatorial cancer treatments by better controlling PK and metabolic differences between drugs.
Export Options
About this article
Cite this article as:
Liu Yarong, Rohrs Jennifer and Wang Pin, Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies, Current Drug Metabolism 2014; 15 (8) . https://dx.doi.org/10.2174/1389200216666150223152958
DOI https://dx.doi.org/10.2174/1389200216666150223152958 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Exploring oxidative stress and the anti-oxidant defense system in chronic diseases: therapeutic strategies and future perspective
Ageing is facilitated by oxidative stress (OS), which happens spontaneously. Several studies have demonstrated that OS over an extended period of time has a role in the emergence of several chronic illnesses. Diabetes, cancer, and heart disease are a few examples of these ailments. An imbalance between the body's antioxidants ...read more
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Tankyrase Inhibitors as Therapeutic Targets for Cancer
Current Topics in Medicinal Chemistry Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
Current Radiopharmaceuticals Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Liposomes Containing Gadodiamide: Preparation, Physicochemical Characterization, and In Vitro Cytotoxic Evaluation
Current Drug Delivery Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Non-Homologous DNA End Joining in Anticancer Therapy
Current Cancer Drug Targets Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Mechlorethamine based Drug Structures for Intervention of Central Nervous System Tumors
Central Nervous System Agents in Medicinal Chemistry Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Current Neuropharmacology Liposome-Nanogel Structures for Future Pharmaceutical Applications
Current Pharmaceutical Design Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets